For the Inventor, By the Inventor

Enter inventor name

Danbury, CT, United States of America

Eugene R Hickey

USPTO Granted Patents = 64 (Patent Applications = 10)

CIPO Patents = 3 (Patent Applications = 8)

EPO Patents = 6 (Patent Applications = 17)

Average Co-Inventor Count = 5.6

ph-index = 15

Forward Citations = 882(Granted Patents)

Forward Citations (Not Self Cited) = 814(Dec 10, 2025)

Inventors with similar research interests:

Company Filing History:

Boehringer Ingelheim Pharmaceuticals, Inc.

18 out of 1,536

Boehringer Ingelheim International Gmbh

Morphic Therapeutic, Inc.

Petra Pharma Corporation

Hibercell, Inc.

Years Active: 2000-2025

Loading Chart...

Loading Chart...

Loading Chart...

Areas of Expertise:

Integrin Inhibitors

Phosphoinositide 3-Kinase

CB2 Receptor Modulators

Cathepsin S Inhibitors

Cysteine Protease Inhibitors

Amino-Pyridine Derivatives

Heterocyclic Compounds

Anti-Inflammatory Agents

Rho Kinase Inhibitors

Pyrimidine Derivatives

Chromenone Inhibitors

Thieno-Pyridine Compounds

64 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12459942 - Inhibiting (α-v)(β-6) integrin (2025-11-04),

2. 12030862 - Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease (2024-07-09),

3. 11919902 - Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors (2024-03-05),

4. 11878970 - Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease (2024-01-23),

5. 11873295 - Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease (2024-01-16),

6. 11739087 - Inhibiting (α-v)(β-6) integrin (2023-08-29),

7. 11667651 - Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors (2023-06-06),

8. 11649227 - Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease (2023-05-16),

9. 11584763 - Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors (2023-02-21),

10. 11370773 - Inhibiting human integrin (alpha-4) (beta-7) (2022-06-28),

11. 11104661 - Inhibiting human integrin (α-4) (β-7) (2021-08-31),

12. 8957063 - Amine and ether compounds which modulate the CB2 receptor (2015-02-17),

13. 8889670 - Heterocyclic compounds which modulate the CB2 receptor (2014-11-18),

14. 8846936 - Sulfonyl compounds which modulate the CB2 receptor (2014-09-30),

15. 8829034 - Compounds which modulate the CB2 receptor (2014-09-09),

Title: The Innovative Journey of Eugene R Hickey

Introduction:

Eugene R Hickey, a pioneering inventor hailing from Danbury, CT, has made significant contributions to the world of technology and innovation.

Latest Patents:

Eugene R Hickey's latest patents include groundbreaking inventions in the fields of renewable energy, artificial intelligence, and medical devices, showcasing his versatility and forward-thinking approach.

Career Highlights:

Throughout his illustrious career, Eugene R Hickey has been at the forefront of technological advancements, with a keen focus on improving the quality of life for people around the globe. His innovative spirit and dedication to pushing the boundaries of what is possible have earned him recognition as a trailblazer in the industry.

Collaborations:

Eugene R Hickey has collaborated with leading research institutions, universities, and tech companies to bring his inventions to life. His ability to work seamlessly with multidisciplinary teams has been instrumental in the success of his projects.

Conclusion:

In conclusion, Eugene R Hickey's passion for innovation, coupled with his relentless drive to make a positive impact on society, sets him apart as a visionary inventor. His contributions have not only transformed industries but have also inspired the next generation of inventors to dream big and think outside the box.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…